매출 하락 → 마진 압박 → 현금 악화
Critical매출이 -34.4% 감소하며 영업이익률이 -82.4%에서 -180.0%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.
Evidence
Xencor's company information is shown as of 2026-11-20. It is a security listed on Nasdaq, ticker XNCR. There are 14 published related companies.
Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics to treat cancer and autoimmune diseases. Xencor develops and advances XmAb drug candidates and biotherapeutic drug candidates. Xencor focuses its business, research, and clinical efforts on developing and advancing a portfolio of XmAb drug candidates in oncology and autoimmune diseases.
Quantus's relationship data lists competitors: Amgen, Genmab, MacroGenics and 5 more; customers: AstraZeneca, Novartis, Johnson & Johnson.
By revenue it ranks No. 263 of the 531 companies with revenue data in Healthcare, with less than 0.1% of the sector's total revenue.
The sector is fragmented: its top three companies hold 37.1% of revenue.
Source: 10-K FY2025 · SEC, business description (filed 2026-02-25)
Auditable observations with the original numeric evidence.
매출이 -34.4% 감소하며 영업이익률이 -82.4%에서 -180.0%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.
Evidence
Factual information, not investment advice.
A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F is quarterly and may be filed up to 45 days later.
A curated subset of well-known investors — not the full institutional ownership.
US name matches 2974/3610 · KR cache checked 3595/3595 stocks
Factual filing information, not investment advice.
2026-11-21 dataset
Passive money holding this stock ≈ $1M(lower bound — top-10 basis, not a forecast)
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →